Radiopharmaceuticals 101: What Every Biotech Leader Needs to Know Before Diving In

Intro

Radiopharmaceuticals are redefining precision medicine. But they’re not like traditional drugs—and diving in without a roadmap can be risky. Here’s what biotech leaders need to know before getting started.

The Opportunity Is Real—And Complex

Radiopharmaceuticals are targeted agents that deliver radioactive isotopes directly to tumors. They allow clinicians to both see and treat disease at the molecular level—ushering in a new era of precision medicine.

With recent approvals like Novartis’ Pluvicto^® for prostate cancer and Lutathera^® for neuroendocrine tumors, the field is gaining traction. These agents offer more than incremental benefit—they represent a shift in how certain cancers are diagnosed and managed. But the development path is anything but straightforward. Success demands early integration of imaging, isotope logistics, trial design, regulatory compliance, and site readiness.¹

What makes radiopharmaceuticals so compelling is their potential to combine diagnosis and treatment into a single paradigm. By using imaging to identify patients most likely to benefit, and then delivering a therapeutic payload to the same target, developers can design more efficient, personalized clinical programs. But unlocking this potential requires a nuanced understanding of how radiopharmaceuticals work—and how they are developed.

It’s Not Just Another Drug Program

Unlike conventional therapies, radiopharmaceuticals come with a unique set of challenges:

• Radioactive decay means short shelf life.

• Dual regulatory oversight involves both drug and radiation authorities.

• Companion imaging is often mandatory for patient selection.

• Infrastructure gaps can prevent clinical trial execution.

These aren’t minor operational issues—they’re make-or-break factors. A lack of readiness in any of these areas can derail an otherwise promising program.²

Equally important is a regulatory strategy that accounts for both the therapeutic and diagnostic components. In many jurisdictions, each may require separate filings, data sets, and compliance pathways.

Smarter Trials, Smaller Trials

One of the most strategic advantages of radiopharmaceutical development is its potential to optimize patient selection and trial design. When the diagnostic component is used to identify the right patients, trials can be smaller, more targeted, and faster to execute.

For instance, in the development of Pluvicto^®, patients were enrolled based on PSMA PET imaging. This ensured that only those with the target biology received the treatment, increasing response rates and trial efficiency. Modeling studies show that even when the target is highly prevalent, trial size can be reduced by 10–13% through pre-selection strategies.³

This design efficiency not only accelerates timelines—it reduces costs and enhances the likelihood of clinical success. But these benefits only materialize when diagnostic thresholds are validated, imaging is standardized across sites, and regulatory engagement begins early.

Regulatory Readiness Is Essential

Radiopharmaceuticals straddle traditional drug development and nuclear medicine, which introduces regulatory complexity. The FDA, EMA, and IAEA have each advanced new frameworks for these agents, but harmonization remains incomplete—particularly in emerging markets.

Many countries still require separate approvals for the diagnostic and therapeutic components. Delays often occur when imaging agents are treated as ancillary, rather than essential, to the therapeutic program.⁴

Successful programs address this by integrating diagnostic and therapeutic pathways from the outset, ensuring that dosimetry, imaging reproducibility, and radiation safety are fully aligned with the trial’s therapeutic objectives.⁵

Understanding and aligning with these frameworks early is critical—especially when it comes to dosimetry, diagnostic-therapeutic integration, and site licensing.⁴ ⁵

What Trips Teams Up

Even experienced sponsors can run into trouble. Common missteps include:

• Underestimating isotope supply chain fragility.

• Inadequate planning for site and radiopharmacy readiness.

• Poor coordination of imaging-read protocols across geographies.

• Regulatory gaps between the diagnostic and therapeutic components.

These issues aren’t theoretical—they’ve derailed otherwise strong programs. That’s why domain-specific execution matters.

How Theragnostic Insights Can Help

At Theragnostic Insights, we embed radiopharmaceutical strategy into your program from day one. Our team supports:

• Trial design and diagnostic integration

• Site selection and readiness

• Isotope supply chain coordination

• Regulatory pathway development

Whether you’re planning your first-in-human study or advancing toward registration, we deliver the structure, speed, and expertise to help you succeed.

The Bottom Line

Radiopharmaceuticals are powerful—but they are not plug-and-play. For teams willing to engage early and build thoughtfully, the clinical and commercial upside is substantial.

You don’t have to go it alone. Let’s build it right—together.

‍

References:

[1] Giammarile F, et al., 2024. Production and Regulatory Issues for Theragnostics. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(24)00041-X

[2] Korde A, et al., 2024. Position paper to facilitate patient access to radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry. https://doi.org/10.1186/s41181-023-00230-2

[3] Wang SJ, et al., 2022. Theragnostic approach in drug development. Theragnostics. https://www.thno.org/v12p3079.htm

[4] Xiong Y, et al., 2024. A decade of incremental advances in radiopharmaceuticals. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-05891-4

[5] Perera M, Morris MJ., 2022. From Concept to Regulatory Drug Approval: Lessons for Theragnostics. Journal of Nuclear Medicine. https://jnm.snmjournals.org/content/63/12/1793